The effects of a landmark ruling on DNA ownership are becoming clearer

AdobeToday,ifyouwanttoknowwhatscaryfamilyhealthsecretslayburiedinyourDNAorgetscreenedforalurkingcanc SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We




comprehensive

author：explore    Page View：99
Alastair Grant/AP

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

advertisement

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： AltruBio raises $225 million to develop ulcerative colitis drug
Next article： Affirmative action in medical school literally saved lives